# Study to Evaluate 13 Valent Pneumococcal Conjugate Vaccine (13vPnC) Vaccine Followed by 23-valent Pneumococcal Polysaccharide Vaccine (23vPS) Vaccine in Allogeneic Hematopoietic Stem Cell Transplant Recipients

> **NCT00980655** · PHASE3 · COMPLETED · sponsor: **Pfizer** · enrollment: 251 (actual)

## Conditions studied

- Vaccines, Pneumococcal Conjugate Vaccine

## Interventions

- **BIOLOGICAL:** 13vPnC
- **BIOLOGICAL:** 23vPS

## Key facts

- **NCT ID:** NCT00980655
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-01-18
- **Primary completion:** 2013-05-16
- **Final completion:** 2013-05-16
- **Target enrollment:** 251 (ACTUAL)
- **Last updated:** 2018-12-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00980655

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00980655, "Study to Evaluate 13 Valent Pneumococcal Conjugate Vaccine (13vPnC) Vaccine Followed by 23-valent Pneumococcal Polysaccharide Vaccine (23vPS) Vaccine in Allogeneic Hematopoietic Stem Cell Transplant Recipients". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT00980655. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*